Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT
Harnessing its automated cell culturing and digital technology to overcome intractable diseases
TOKYO, Jul 06, 2023 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501, "Hitachi") announced that it has entered a strategic framework collaboration agreement with the world-renowned medical research institution, Brigham and Women's Hospital (BWH), a founding member of the Mass General Brigham healthcare system and a teaching affiliate of the Harvard Medical School,(1) on 29 June, to establish a joint site for "co-creation" to accelerate efforts in gene and cell therapy (GCT) to conquer intractable diseases and realize practical applications.
Outline of the joint research
By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases. For example, the therapeutic efficacy of CAR-T(2) cells which are thought to recognize and attack cancer cells can only be decisively confirmed through in-human clinical trials. Therefore, it is important to first establish a disease "model" to accurately predict the clinical safety and efficacy of the therapy by studying the behavior of CAR-T cells on cancer cells cultivated in a laboratory environment. The goal is to develop new disease models through this joint research and contribute to increasing the scope of GCT application to various diseases.
Hitachi will also contribute to the advancement of GCT through cell culturing and the development of the culturing process required in GCT by bringing research achievements and business experience in the field of regenerative medicine and GCT. In addition, Hitachi is developing a highly efficient technique to create genetically modified cells for GCT, and from this collaboration framework will look to apply this technology in the development of new therapy with researchers and pharmaceutical companies in the US and worldwide.
Roger Hajjar, M.D., head of the Mass General Brigham GCTI, commented, "We welcome Hitachi as our first industry collaborator and are looking forward to working together to accelerate the development and early commercialization of GCT using Hitachi's novel platform."
Mass General Brigham is a world-leading eco-system for GCT research and clinical trials, with over 400 researchers working on ground-breaking gene and cell therapy research and treatment in pursuit of potential cures.
Hitachi has a strong track record in the healthcare area, driving innovation and delivering comprehensive solutions. Under its Mid-term Management Plan 2024, Hitachi remains committed to driving radical innovation based on back casting from 2050 to realize an environmentally neutral society where people can enjoy longevity in a comfortable and active way, and where humans and digital technology can evolve together. GCT research is one key initiative in this pursuit. Hitachi will leverage its diverse technology portfolio which includes automated cell culturing technology and digital technology to contribute to the practical application of new treatments pioneered by MGB.
Background
GCT is a form of treatment delivering specific target genes or genetically-modified cells related to a disease, and is expected to be applicable to a wide range of difficult to treat diseases such as certain types of cancers, cardiovascular, pulmonary, musculo-skeletal, neurodegenerative and autoimmune diseases, and rare diseases.
From an early stage, Mass General Brigham has been actively engaged in GCT research, creating GCTI in December 2022. (3) GCTI is establishing an organization and research environment to accelerate the discovery and creation of new medical and biological seeds that will lead to the development of novel therapies. Mass General Brigham aims to conduct clinical trials in its affiliated hospitals to develop and commercialize the new life-changing therapies and is recruiting leading scientists conducting cutting-edge projects from around the world as well as establishing an industry-academia ecosystem to support this.
Hitachi has actively promoted open innovation, participating in a national project to collaborate with academia and pharmaceutical companies (4) to ensure that regenerative medicine and GCT will become available to all those in need, and has worked to develop its closed-system aseptic automated cell culture technology. In 2019, they successfully launched the automated cell culture system and delivered it to Sumitomo Dainippon Pharma Co., Ltd.'s cell manufacturing plant for induced pluripotent stem (iPS) cells for iPS cell-based therapies. In 2020, Hitachi's equipment was used for the first time in clinical studies when Sumitomo Dainippon Pharma Co., Ltd. was selected to supply the iPS cell-derived dopamine neural precursors for transplantation in the Kyoto University-led clinical trials to develop treatment for Parkinson's disease using regenerative medicine.
(1) About Mass General Brigham (2) CAR-T cells: Chimeric Antigen Receptor T-cell. T cells are a type of white blood cell (lymphocyte) that plays a crucial role in the immune system by attacking "foreign" bodies. In CAR-T cells, the T cells that have been genetically modified to express a chimeric antigen receptor on their surface that recognizes and attaches itself to specific proteins or antigens, especially those present on cancer cells. The use of CAR-T cells was first approved in the US in 2017 after it was shown to be highly effective in the treatment of B-cell acute lymphoblastic leukemia and malignant lymphoma. The treatment involves the modification of T-cells collected from the peripheral blood of the patient, culturing the CAR-T cells to increase their number and re-introducing them into the patient's body. (3) Gene Therapy Pioneer Roger Hajjar, MD, Named Director of Mass General Brigham Gene and Cell Therapy Institute (4) New Energy and Industrial Technology Development Organization (NEDO) "Fundamental Technology Research Promotion Project", Cabinet Office "Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST)," MEXT "Program for Formation of Innovation Center for Advanced Interdisciplinary Fields under the Innovation System Development Project", Japan Agency for Medical Research and Development (AMED), "Development of Evaluation Basic Technology for Industrialization of Regenerative Medicine," etc.
About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the business structure of "Digital Systems & Services" - supporting our customers' digital transformation; "Green Energy & Mobility" - contributing to a decarbonized society through energy and railway systems, and "Connective Industries" - connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company's consolidated revenues for fiscal year 2022 (ended March 31, 2023) totaled 10,881.1 billion yen, with 696 consolidated subsidiaries and approximately 320,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.
Source: Hitachi, Ltd. Sectors: MedTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Release
 MHIEC Receives Order from the Bureau of Sewerage of the Tokyo Metropolitan Government for Rebuilding of Sewage Sludge Incineration Facility Apr 17, 2025 14:44 JST
|  Fujitsu collaboration with Supermicro and Nidec to reduce data center energy consumption Apr 17, 2025 10:32 JST
| Fujitsu's Japanese language enhanced LLM Takane offering now available on Nutanix Enterprise AI solution Apr 16, 2025 11:24 JST
|  Isuzu and Fujitsu sign partnership agreement to commercialize software defined vehicles Apr 15, 2025 12:29 JST
|  MHI Awarded a Study on CO2 Capture Modules for FPSOs Apr 15, 2025 10:46 JST
|  Mitsubishi Motors Begins Shipping Xforce HEV Model in Thailand Apr 11, 2025 15:03 JST
|  Collaboration to Make Engine-Equipped Vehicles Carbon Neutral Using Synthetic Fuel Apr 11, 2025 14:03 JST
|  TGR to Launch Evolved GR Yaris Apr 11, 2025 13:35 JST
|  Fujitsu develops employee training platform for Seven-Eleven Japan to accelerate store digitalization Apr 11, 2025 11:29 JST
|  Mitsubishi Corporation makes DennoKotsu an equity-method affiliate company, strengthening efforts to address regional transportation challenges Apr 11, 2025 10:39 JST
|  JCB Enhances Customer Experience with Expanded Payment Acceptance for App Store and Apple Services in Asia Apr 11, 2025 10:00 JST
|  Fujitsu and Headwaters trial on-device generative AI solution to streamline JAL cabin crew workflows Apr 11, 2025 09:07 JST
|  Mitsubishi Logisnext Delivers Container Terminal Gate System with Enhanced Functionality to Port of Osaka Apr 10, 2025 16:23 JST
|  Mitsubishi Shipbuilding Acquired Approval in Principle (AiP) from Classification Society for the Basic Design of an Onboard Carbon Capture and Storage System Apr 10, 2025 14:17 JST
|  Honda NC750X Named Winner in 2025 Red Dot Design Award: Product Design Category, EM1 e: Wins 2025 iF Design Award: Product Design Category Apr 10, 2025 13:13 JST
|  Mitsubishi Corporation to Participate in Demonstration Project for New Hydrogen-Based Ironmaking Apr 09, 2025 18:22 JST
|  SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis Apr 09, 2025 15:49 JST
|  Intelligent Joy Limited Signs MOU with Smart IR and CLS Press to Collaborate on AI-Driven Investor Relations Platform Apr 09, 2025 14:57 JST
|  MHIEC Completes Refurbishment of Core Facilities of Waste-to-Energy Plant in Miyazaki City Apr 09, 2025 14:19 JST
|  NEC Face Recognition Ranks First in NIST Accuracy Testing Apr 09, 2025 11:09 JST
|
More Latest Release >>
|